Hologic (HOLX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.93 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has surpassed consensus EPS estimates four times. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earn ...

Hologic Announces Financial Results for Third Quarter of Fiscal 2024 "In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Our strong fiscal quarter and year-to-date results continue to highlight the durable strength across our broad portfolio, with our Diagnostics (ex-COVID), Breast Health, and Surgical ...

Hologic, Inc. (HOLX) announced that it has completed the previously announced acquisition of Endomagnetics Limited (Endomag), a UK-based developer of breast cancer surgery technologies, for approximately $310 million. This strategic move aims to bolster Hologic's breast surgery portfolio, offering surgeons and radiologists an expanded range of innovative solutions for breast cancer procedures. The acquisition reflects Hologic's commitment to advancing women's health and improving patient outcomes through cu ...

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. Given this perspective, it's time to examine the average forecasts of specific Hologic metrics that are routinely monitored and predicted by Wall Street analysts. Analysts' assessment points toward 'Revenue- GYN Surgical' reaching $166.70 million. The estimate points to a chan ...

In the latest market close, Hologic (HOLX) reached $78.38, with a +0.35% movement compared to the previous day. This change lagged the S&P 500's 1.08% gain on the day. Meanwhile, the Dow experienced a rise of 0.32%, and the technology-dominated Nasdaq saw an increase of 1.58%. For the full year, the Zacks Consensus Estimates project earnings of $4.08 per share and a revenue of $4.04 billion, demonstrating changes of +3.03% and +0.13%, respectively, from the preceding year. Based on our research, we believe ...

Also, in April 2024, Hologic secured an Innovative Technology contract from Vizient for its CoolSeal advanced energy portfolio and JustRight 5 mm stapler. The recognition by Vizient's team of experts underscores the potential of these technologies to enhance clinical care, patient safety and healthcare worker safety and improve the business operations of healthcare organizations. We expect this development to have a positive impact on Hologic's revenues in the fiscal third quarter. Hologic, Inc.'s (HOLX) GY ...

Price-to-Earnings Forward Twelve Months (F12M) Image Source: Zacks Investment Research The stock also appears cheaper in comparison to QGEN and ABT, which are trading at 19.36X and 21.02X, respectively. Investment Thesis Hologic's future growth prospects are highlighted by its impressive portfolio of products regardless of macroeconomic hurdles. In the Molecular Diagnostics business, the company has expanded both the worldwide Panther footprint and menu, with the BV and CV/TV assays and the Biotheranostics ...

Coming into today, shares of the medical device maker had gained 8.27% in the past month. In that same time, the Medical sector gained 0.71%, while the S&P 500 gained 3.82%. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Hologic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Looking at its ...

It's also important to note that HOLX currently trades at a PEG ratio of 2.47. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Instruments was holding an average PEG ratio of 2.47 at yesterday's closing price. Hologic (HOLX) closed the latest trading day at $74.53, indicating a +0.58% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0 ...

However, a deteriorating geopolitical situation, supply chain bottlenecks leading to a tough situation related to raw material and labor costs, freight charges, as well as healthcare staffing shortages, have put the industry in a tight spot again. Meanwhile, industry players like Hologic, Inc. (HOLX) , Masimo Corporation (MASI) and Veracyte, Inc. (VCYT) have adapted well to changing consumer preferences and are still witnessing an uptrend in their stock prices. The Zacks Medical - Instruments industry is hi ...